Skip to main content

Biomedical Research Legislation

This page provides summaries of legislation proposed in the 117th Congress affecting biomedical research policy. This page will be updated as relevant legislation is introduced.

Research Investment to Spark the Economy (RISE) Act (S.289)

  • This legislation was introduced by Senators Edward J. Markey (D-MA), Thom Tillis (R-NC), Gary Peters (D-MI), and Susan Collins (R-ME) on 2/5/2021. It was referred to the Committee on Health, Education, Labor, and Pensions in the Senate.
  • A companion bill was introduced in the House (H.R.869) on 2/5/2021 by lead sponsors Rep. Diana DeGette (D-CO) and Rep. Fred Upton (R-MI).  The house bill was referred to the House Committees on Science, Space, and Technology; Agriculture; Armed Services; Education and Labor; Energy and Commerce; Natural Resources; and Transportation and Infrastructure.
  • This bill would authorize federal agencies to provide support for research regarding COVID-19 or research disrupted by the COVID-19 pandemic. It would provide supplemental funding to extend the duration of grants to research institutions or national laboratories, as well competitively awarded cooperative agreements.

Gabriella Miller Kids First Research Act 2.0 (H.R. 623)

  • This legislation was introduced by Reps. Jennifer Wexton (D-VA), Tom Cole (R-OK) and colleagues on 1/28/2021. It was referred to the House Committees on Energy & Commerce and Financial Services.
  • This bill would direct certain penalties assessed by the Securities Exchange Commission against pharmaceutical companies for specified violations to the 10-Year Pediatric Research Initiative Fund, an existing fund that supports pediatric disease research through the National Institutes of Health (NIH) Common Fund. In making allocations from that fund, the bill directs NIH to prioritize pediatric research that does not duplicate existing research activities.
     
  • Updated: